© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 1, 51-56,
January 3, 2001
© 2001 Oxford University Press
REPORT |
Digitized Mammography: a Clinical Trial of Postmenopausal Women Randomly Assigned to Receive Raloxifene, Estrogen, or Placebo
Affiliations of authors: M. Freedman, S.-C. B. Lo, J. Zeng, Georgetown University Medical Center, Washington, DC; J. San Martin, E. L. Walls, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN; J. O'Gorman, Biogen, Cambridge, MA; S. Eckert, Applied Logic Associates, Inc., Houston, TX; M. E. Lippman, Lombardi Cancer Center, Georgetown University Medical Center.
Correspondence to: Matthew Freedman, M.D., M.B.A., Georgetown University Medical Center, Suite 603, 2115 Wisconsin Ave., N.W., Washington, DC 20007 (e-mail:Freedmmt{at}georgetown.edu).
Background: High mammographic density is associated with increased breast cancer risk. Previous studies have shown that estrogens increase breast density on mammograms, but the effect on mammographic density of selective estrogen receptor modulators, such as raloxifene, is unknown. We assessed changes in mammographic density among women receiving placebo, raloxifene, or conjugated equine estrogens in an osteoporosis prevention trial. Methods: In a 5-year multicenter, double-blind, randomized, placebo-controlled osteoporosis prevention trial, healthy postmenopausal women who had undergone hysterectomy less than 15 years before the study and had no history of breast cancer received placebo, raloxifene (at one of two doses), or conjugated estrogens (ERT). Women from English-speaking investigative sites who had baseline and 2-year craniocaudal mammograms with comparable positioning (n = 168) were eligible for this analysis. Changes in mammographic density were determined by digital scanning and computer-assisted segmentation of mammograms and were analyzed with the use of analysis of variance. All statistical tests were two-sided. Results: Among the four treatment groups after 2 years on study, the mean breast density (craniocaudal view) was statistically significantly greater in the ERT group than it was in the other three groups (P<.01 for all three comparisons). Within treatment groups, the mean breast density from baseline to 2 years decreased statistically significantly in women receiving the placebo or either the higher or lower raloxifene dose (P = .003, P = .002, and P<.001, respectively) and showed a nonstatistically significant increase in women receiving ERT. Conclusions: In an osteoporosis prevention trial, raloxifene did not increase breast density after 2 years of treatment. Raloxifene administration should not interfere with, and could even enhance, mammographic detection of new breast cancers.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. J.B. van Duijnhoven, P. H.M. Peeters, R. M.L. Warren, S. A. Bingham, P. A.H. van Noord, E. M. Monninkhof, D. E. Grobbee, and C. H. van Gils Postmenopausal Hormone Therapy and Changes in Mammographic Density J. Clin. Oncol., April 10, 2007; 25(11): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Fabian and B. F. Kimler Mammographic Density: Use in Risk Assessment and as a Biomarker in Prevention Trials J. Nutr., October 1, 2006; 136(10): 2705S - 2708S. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Maskarinec, I. Pagano, G. Lurie, and L. N. Kolonel A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 732 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J.B. van Duijnhoven, P. H.M. Peeters, R. M.L. Warren, S. A. Bingham, A. G. Uitterlinden, P. A.H. van Noord, E. M. Monninkhof, D. E. Grobbee, and C. H. van Gils Influence of Estrogen Receptor {alpha} and Progesterone Receptor Polymorphisms on the Effects of Hormone Therapy on Mammographic Density. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 462 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. McTiernan, C. F. Martin, J. D. Peck, A. K. Aragaki, R. T. Chlebowski, E. D. Pisano, C. Y. Wang, R. L. Brunner, K. C. Johnson, J. E. Manson, et al. Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized Trial J Natl Cancer Inst, September 21, 2005; 97(18): 1366 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. FREEDMAN Improved Small Volume Lung Cancer Detection with Computer-Aided Detection: Database Characteristics and Imaging of Response to Breast Cancer Risk Reduction Strategies Ann. N.Y. Acad. Sci., May 1, 2004; 1020(1): 175 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Harvey and V. E. Bovbjerg Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk Radiology, January 1, 2004; 230(1): 29 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. DRAPER The Role of Selective Estrogen Receptor Modulators (SERMs) in Postmenopausal Health Ann. N.Y. Acad. Sci., November 1, 2003; 997(1): 373 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Gann and M. Morrow Combined Hormone Therapy and Breast Cancer: A Single-Edged Sword JAMA, June 25, 2003; 289(24): 3304 - 3306. [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski and A. McTiernan Biological Significance of Interventions That Change Breast Density J Natl Cancer Inst, January 1, 2003; 95(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
|
|
G. A. Greendale, B. A. Reboussin, S. Slone, C. Wasilauskas, M. C. Pike, and G. Ursin Postmenopausal Hormone Therapy and Change in Mammographic Density J Natl Cancer Inst, January 1, 2003; 95(1): 30 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Johnell, W. H. Scheele, Y. Lu, J.-Y. Reginster, A. G. Need, and E. Seeman Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 985 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. BARRETT-CONNOR Raloxifene: Risks and Benefits Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 295 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Lippman, K. A. Krueger, S. Eckert, A. Sashegyi, E. L. Walls, S. Jamal, J. A. Cauley, and S. R. Cummings Indicators of Lifetime Estrogen Exposure: Effect on Breast Cancer Incidence and Interaction With Raloxifene Therapy in the Multiple Outcomes of Raloxifene Evaluation Study Participants J. Clin. Oncol., June 15, 2001; 19(12): 3111 - 3116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Torgerson and S. E. M. Bell-Syer Hormone Replacement Therapy and Prevention of Nonvertebral Fractures: A Meta-analysis of Randomized Trials JAMA, June 13, 2001; 285(22): 2891 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Mammographic Breast Density: Effect of Raloxifene Journal Watch Women's Health, March 6, 2001; 2001(306): 7 - 7. [Full Text]
|
|